We’re thrilled to announce a new strategic alliance between ExSyn, Exim-Indis and simABs, a leading EU-based biologics manufacturer known for its patented continuous flow technology in antibody production.
ExSyn and Exim-Indis will now represent simABs in the Indian and the U.S. markets respectively —bringing their innovative, high-quality antibodies to researchers, biotech companies, and healthcare providers.
simAbs: Smart Integrated Manufacturing of ATMP’s and Biologics
simAbs provides the full range of services and support for biologics development and GMP manufacturing, specializing in sustainable biomanufacturing technologies.
For more details, please visit:
https://www.simabs.com/
Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.
5-Methyl-3-vinyl-2-oxazolidinone (V-MOX) is a highly reactive monomer valued for its low viscosity, mild odor, and excellent reactivity. It is widely used as a reactive diluent in UV-curable inks and coatings, where it enhances adhesion, produces brighter colors, and improves safety compared to conventional diluents. In addition, V-MOX serves as a key building block in the synthesis of kinetic hydrate inhibitor (KHI) polymers, which are applied in oil and gas production to prevent hydrate blockages in pipelines.
Zinc ricinoleate is the zinc salt of ricinoleic acid, a hydroxylated fatty acid derived mainly from castor oil (Ricinus communis). It appears as a white to slightly yellowish powder, waxy solid, or paste, depending on formulation. Its most valuable property is its ability to trap and absorb odor molecules such as amines, sulfides, and short-chain fatty acids, making it an essential ingredient in deodorant and odor-control products.
The economic impact of biosimilars on the Australian health care system is now clearer, with data revealing their role in reducing market expenditure and driving price competition.